Skip to main content
SpringerLink
Log in

The role of monoclonal antibody A7 as a drug modifier in cancer therapy

  • Original articles
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

An anticancer antibiotic, neocarzinostatin (NCS), was covalently conjugated to the murine monoclonal antibody A7 (mAb A7), which recognizes the glycoprotein on the cell surface of human colon cancer. The biological and pharmacological properties of the conjugate (A7-NCS) were examined and compared with those of unconjugated NCS. A7-NCS exhibited a strong binding and cytotoxicity to the cell and an antigen-specific tumor accumulation. Significant tumoricidal effects in vivo were observed in the antigen-positive tumor-bearing mice treated with A7-NCS, whereas NCS mixed with mAb A7 and NCS alone were relatively ineffective. In the antigennegative tumor, the tumoricidal effect of A7-NCS was lower than in the antigen-positive tumor. The NCS concentration in blood and tumor were significantly elevated by conjugation to mAb A7. The NCS localization in tumor was higher in the antigen-positive tumor than in the antigen-negative tumor. Death due to acute toxicity was observed at a dose of 20 units (U) NCS in mice treated with unconjugated NCS, whereas toxicity was seen with a much higher dose of NCS (100 U) if the drug was conjugated to the mAb. These findings show that mAb A7 confers more favorable pharmacological properties on an anticancer drug, making it potentially more useful for cancer chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Arnon R, Sela M (1982) In vitro and in vivo efficacy of conjugates of daunomycin with anti-tumor antibodies. Immunol Rev 62: 5–27

    Google Scholar 

  2. Atsumi R, Endo K, Kakutani T, Takakura Y, Hashida M, Sezaki H (1987) Disposition characteristics of mytomycin C-dextran conjugate in normal and tumor bearing muscles of rabbits. Cancer Res 47: 5546–5551

    Google Scholar 

  3. Davis SS, Illum L (1986) Colloidal delivery systems-opportunities and challengers. In: Tomlinson E, Davis SS (eds) Site-specific drug delivery: cell biology. Medical and pharmaceutical aspects. Wiley, Chichester, pp 93–110

    Google Scholar 

  4. Dillman RO, Johnson DE, Shawler DL, Koziol JA (1988) Supeority of an acid-labile daunomycin-monoclonal antibody immunoconjugate compared to free drug. Cancer Res 48: 6097–6102

    Google Scholar 

  5. Ebina T, Ohtsuki K, Seto M, Ishida N (1975) Specific G2 block in Hela-S3 cells by neocarzinostatin. Eur J Cancer 11: 155–158

    Google Scholar 

  6. Fujimori K, Covell DG, Fletcher JE, Weinstein JN (1989) Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab′)2 and Fab in tumors. Cancer Res 49: 5656–5663

    Google Scholar 

  7. Fujita H, Nakayama N, Sawabe T, Kimura K (1970) In vivo distribution of and inactivation of neocarzinostatin (in Japanese). Jpn J Antibiot 23: 471–478

    Google Scholar 

  8. Fukuda K (1985) The study of targeting chemotherapy against the gastrointestinal cancer (the preparation of anticancer drug-monoclonal antibody conjugate and the investigation about its biological activity (in Japanese). Akita J Med 12: 451–468

    Google Scholar 

  9. Gallego J, Price MR, Baldwin RW (1984) Preparation of four daunomycin-monoclonal antibody 791T/36 conjugates with anti-tumor activity. Int J Cancer 33: 737–744

    Google Scholar 

  10. Garnett MC, Embleton MJ, Jacob E, Baldwin RW (1983) Preparation and properties of a drug-carrier-antibody conjugates showing selective antibody-directed cytotoxicity in vitro. Int J Cancer 31: 661–670

    Google Scholar 

  11. Greenwood FC, Hunter WM, Glover JS (1963) The preparation of 131-I labeled human growth hormone of high specific radioactivity. Biochem J 89: 114–123

    Google Scholar 

  12. Gregoriads G, Senior J, Wolff B, Kirby C (1984) Fate of liposomes in vivo control leading to targeting. In: Gregoriadis G, Poste G, Senior J, Trouet A (eds) Receptor-mediated targeting of drugs. Plenum, New York, pp 243–266

    Google Scholar 

  13. Hagiwara A, Takahashi T, Lee R, Ueda T, Takeda M, Itoh T (1987) Chemotherapy for carcinoma peritonitis and pleuritis with MMCCH, mitomycin C adsorbed on activated carbon particles. Cancer 59: 245–251

    Google Scholar 

  14. Hirano T, Ohashi S, Morimoto S, Tsukada K, Kobayashi T, Tsukagoshi S (1986) Synthesis of antitumor-active conjugates of Adriamycin or daunomycin with the copolymer of divinyl ether and maleic anhydride. Makromol Chem 187: 2815–2824

    Google Scholar 

  15. Hoes CJT, Potman W, von Heeswijk WA, Mud RJ, de Mooth BG, Greve J, Feijen J (1985) Optimization of macromolecular prodrugs of the antitumor antibiotics Adriamycin. J Controlled Release 2: 205–213

    Google Scholar 

  16. Ishida N, Miyazaki K, Kumagai K, Rikimaru M (1965) Neocarzinostatin, an antitumor antibiotic of high molecular weight. J Antibiot (Tokyo) 18: 68–71

    Google Scholar 

  17. Kanellos J, Pietersz GA, Mckenzie IFC (1985) Studies of methotrexate-monoclonal antibody conjugate or immunotherapy. JNCI 75: 319–332

    Google Scholar 

  18. Kinami Y, Miyazaki H, Koyama F, Noguchi M, Konishi T, Furukawa S, Nishida Y, Miyazaki I (1975) The treatment of pancreatic carcinoma with neocarzinostatin (in Japanese). J Jpn Soc Cancer Ther 10: 502–508

    Google Scholar 

  19. Kitamura K, Takahashi T, Yamaguchi T, Yokota T, Noguchi A, Amagai T, Imanishi J (1989) Immunochemical characterization of the antigen recognized by the murine monoclonal antibody A7 against human colorectal cancer. Tohoku J Exp Med 157: 83–93

    Google Scholar 

  20. Kitamura K, Takahashi T, Tsurumi H, Takashina K, Noguchi A, Noguchi AK, Okuzumi J, Yamaguchi T (1991) Pharmacokinetical analysis of the monoclonal antibody A7-neocarzinostatin conjugate adminstered to nude mice. Tohoku J Exp Med 164: 203–211

    Google Scholar 

  21. Kitazima K (1974) The clinical evaluation of a new antileukemic agent. Neocarzinostation (in Japanese). Acta Haematol Jpn 37: 767–772

    Google Scholar 

  22. Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495–497

    Google Scholar 

  23. Kotanagi H, Takahashi T, Masuko T, Hashimoto Y, Koyama K (1986) A monoclonal antibody against human colon cancers. Tohoku J Exp Med 148: 353–360

    Google Scholar 

  24. Lazarus H, Raso V, Samy TSA (1977) In vitro inhibition of human leukemic cells (CCRF-CEM) by agarose-immobilized neocarzinostatin. Cancer Res 37: 3731–3736

    Google Scholar 

  25. Mukojima T, Kimura K (1974) Immunological assay of neocarzinostatin (in Japanese). Jpn J Cancer Clin 20: 245–248

    Google Scholar 

  26. Napier MA, Holmquist B, Strydam DJ, Goldenberg IH (1979) Neocarzinostatin: spectral characterization and separation of non-protein chromophore. Biochem. Biophys Res Commun 89: 635–642

    Google Scholar 

  27. Okamoto Y, Konno A, Togawa K, Kato T, Tamakawa Y, Amano Y (1986) Arterial chemoembolization with cisplatin microcapsules, Br J Cancer 53: 369–375

    Google Scholar 

  28. Pietersz GA, Smyth MJ, Mckenzie IFC (1988) Immunochemotherapy of a murine thymoma with the use of idarubicin monoclonal antibody conjugates. Cancer Res 48: 926–931

    Google Scholar 

  29. Pimm MV, Jones JA, Price MR, Middle JG, Embleton MJ, Baldwin RW (1982) Tumor localization of monoclonal antibody against a rat mammary carcinoma and suppresion of tumor growth with Adriamycin-antibody conjugate. Cancer 12: 125–134

    Google Scholar 

  30. Pratesi G, Savi G, Pezzoni G, Bellini O, Penco S, Tinelli S, Zunino F (1985) Poly-l-aspartic acid as a carrier for doxorubicin: a comparative in vivo study of free and polymer-bound drug. Br J Cancer 52: 841–848

    Google Scholar 

  31. Sands H, Jones PL, Shah SA, Palme D, Vessela RL, Gallagher BM (1988) Correlation of vascular permeability and blood flow with monoclonal antibody uptake by human Clouser and renal cell xenografts. Cancer Res 48: 188–193

    Google Scholar 

  32. Shockley TR, Lin K, Sung C, Nagy JA, Tompkins RG, Dedrick RL, Dvorak HF, Yarmush ML (1992) A quantitative analysis of tumor specific monoclonal antibody uptake by human melanoma xenografts: effect of antibody immunological properties and tumor antigen expression levels. Cancer Res 52: 357–366

    Google Scholar 

  33. Swabb EA, Wei J, Gullino PM (1984) Diffusion and convection in normal and neoplastic tissues. Cancer Res 34: 2814–2822

    Google Scholar 

  34. Takahashi M, Toriyama K, Maeda H, Kikuchi M, Kumagai K, Ishida N (1969) Clinical trials of a new antitumor polypeptide: neocarzinostatin (NCS) Tohoku J Exp Med 98: 273–280

    Google Scholar 

  35. Takahashi T, Ueda S, Kono K, Majima S (1976) Attempt at local administration of anticancer agents in the form of fat emulsion. Cancer 38: 1507–1514

    Google Scholar 

  36. Tsukada Y, Kato Y, Umemeto N, Takeda Y, Hara T, Hirai H (1984) An anti-alpha-fetoprotein antibody-daunomycin conjugate with a novel poly-l-glutamic acid derivative as intermediate carrier. JNCI 13: 721–729

    Google Scholar 

  37. Yamada N, Ishii K, Zeze F, Nakayama K (1973) Excretion of anticancer and antimicrobial drugs into pancreatic juice (in Japanese). Jpn J Gastroenterol 71: 901–906

    Google Scholar 

  38. Yokoyama M, Miyauchi M, Yamada N, Okano T, Sakurai Y, Kataoka K, Inoue S (1990) Characterization and anticancer activity of the micelle-forming polymeric anticancer drug Adriamycin-conjugated poly(ethyleneglycol)-poly(aspartic acid) block copolymer. Cancer Res 50: 1693–1700

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. First Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kawaramachi-hirokojikajiicho Kamikyo-ku, 602, Kyoto, Japan

    K. Kitamura, T. Miyagaki, N. Yamaoka, H. Tsurumi, A. Noguchi, T. Yamaguchi & T. Takahashi

Authors
  1. K. Kitamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Miyagaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N. Yamaoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. Tsurumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Noguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T. Yamaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. T. Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

This work has been supported in part by a grant-in-aid for cancer research from the Ministry of Education and for the comprehensive 10-year strategy for cancer control from the Ministry of Health and Welfare, Japan

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kitamura, K., Miyagaki, T., Yamaoka, N. et al. The role of monoclonal antibody A7 as a drug modifier in cancer therapy. Cancer Immunol Immunother 36, 177–184 (1993). https://doi.org/10.1007/BF01741089

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01741089

Key words

Search

Navigation